Avalyn Pharma Completes MIST Trial Enrollment, Extends Cash Runway to 2029
Event summary
- Completed enrollment of MIST Phase 2b trial for AP01 with 398 patients, exceeding target by 23.
- Ended Q2 2026 with $413.5 million in cash, projecting runway into 2029.
- Two abstracts accepted for presentation at ERS Congress on AP01 lung tissue distribution and clinical trial design.
- AURA Phase 2 trial for AP02 remains on track; topline data expected late 2027.
The big picture
Avalyn Pharma is advancing its inhaled therapies for rare respiratory diseases, positioning itself as a leader in transforming treatment paradigms. The completion of MIST trial enrollment and extended cash runway highlight the company's strategic focus on long-term pipeline expansion amid a competitive landscape in pulmonary fibrosis treatments.
What we're watching
- Execution Risk
- Whether Avalyn can sustain the pace of clinical trial progress across multiple programs.
- Regulatory Dynamics
- How ERS Congress data presentations may influence regulatory perceptions of AP01's efficacy.
- Financial Strategy
- The pace at which Avalyn will need to secure additional funding beyond 2029.